Nuvalent, Inc.

DB:5AX Stock Report

Market Cap: €8.5b

Nuvalent Management

Management criteria checks 3/4

Nuvalent's CEO is Jim Porter, appointed in Feb 2020, has a tenure of 6.42 years. total yearly compensation is $11.39M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth €22.02M. The average tenure of the management team and the board of directors is 4 years and 4.3 years respectively.

Key information

Jim Porter

Chief executive officer

US$11.4m

Total compensation

CEO salary percentage5.72%
CEO tenure6.4yrs
CEO ownership0.3%
Management average tenure4yrs
Board average tenure4.3yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Jim Porter's remuneration changed compared to Nuvalent's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$450m

Dec 31 2025US$11mUS$652k

-US$425m

Sep 30 2025n/an/a

-US$381m

Jun 30 2025n/an/a

-US$343m

Mar 31 2025n/an/a

-US$301m

Dec 31 2024US$17mUS$627k

-US$261m

Sep 30 2024n/an/a

-US$224m

Jun 30 2024n/an/a

-US$174m

Mar 31 2024n/an/a

-US$146m

Dec 31 2023US$9mUS$603k

-US$126m

Sep 30 2023n/an/a

-US$114m

Jun 30 2023n/an/a

-US$100m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$5mUS$580k

-US$82m

Sep 30 2022n/an/a

-US$73m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$5mUS$424k

-US$46m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$759kUS$335k

-US$15m

Compensation vs Market: Jim's total compensation ($USD11.39M) is above average for companies of similar size in the German market ($USD6.04M).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Porter (50 yo)

6.4yrs
Tenure
US$11,393,602
Compensation

Dr. James R. Porter, also known as Jim, Ph.D. has been Chief Executive Officer and President of Nuvalent, Inc. since February 1, 2020 and has been Director since February 2020. He joined Nuvalent during co...

Leadership Team

NamePositionTenureCompensationOwnership
James Porter
CEO, President & Director6.4yrsUS$11.39m0.26%
€ 22.0m
Alexandra Balcom
CFO & Treasurer5.5yrsUS$4.17m0.11%
€ 9.3m
Deborah Miller
Chief Legal Officer & Secretary5.1yrsUS$4.16m0.023%
€ 2.0m
Darlene Noci
Chief Development Officer5.5yrsUS$4.16m0.022%
€ 1.8m
Christopher Turner
Chief Medical Officer5.3yrsUS$4.24m0.040%
€ 3.4m
Benjamin Lane
Chief Technical Operations Officer4yrsno data0.034%
€ 2.9m
Henry Pelish
Chief Scientific Officer2yrsno data0.025%
€ 2.2m
Chelcie Lister
Senior Director of Investor Relations & Corporate Communicationsno datano datano data
John Soglia
Senior Vice President of Translational Development3.4yrsno datano data
Joshua Horan
Senior Vice President of Chemistry1.2yrsno datano data
Ruth Adams
Senior Vice President of Clinical Operations1.2yrsno datano data
Jessie Lin
Senior Vice President of Corporate Strategy & Portfolio Management1.2yrsno datano data
4.0yrs
Average Tenure
50yo
Average Age

Experienced Management: 5AX's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Porter
CEO, President & Director6.4yrsUS$11.39m0.26%
€ 22.0m
Sapna Srivastava
Independent Non-Executive Director5yrsUS$461.93k0.0065%
€ 556.3k
Grant Bogle
Independent Director1.6yrsUS$449.93k0.0047%
€ 401.7k
Anna Protopapas
Independent Chairman4.3yrsUS$485.43k0.0065%
€ 556.3k
D. Gilliland
Member of Scientific Advisory Board1.1yrsUS$322.22k0%
€ 0
Michael Meyers
Independent Director3.8yrsUS$451.93k0.0065%
€ 556.3k
Cameron Wheeler
Independent Non-Executive Director9.4yrsUS$454.76k0.0065%
€ 556.3k
Alice Shaw
Member of Scientific Advisory Board1.7yrsno datano data
David Ross Camidge
Member of Scientific Advisory Boardno datano datano data
Aaron Hata
Member of Scientific Advisory Boardno datano datano data
Nancy Kohl
Member of Scientific Advisory Boardno datano datano data
Alexander Drilon
Member of Scientific Advisory Board5.3yrsno datano data
4.3yrs
Average Tenure
62yo
Average Age

Experienced Board: 5AX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 16:31
End of Day Share Price 2026/07/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvalent, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Etzer DaroutBarclays
Jeffrey WalchBernstein